Quality Assessment: Stable but Mixed Financial Performance
Alembic Pharmaceuticals operates within the Pharmaceuticals & Biotechnology sector, classified as a small-cap company with a market capitalisation reflecting its niche positioning. The company’s financial quality remains mixed. While the latest quarter (Q4 FY25-26) reported flat financial results, Alembic maintains a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 1.28 times. This indicates prudent financial management and a manageable leverage profile.
Return on Capital Employed (ROCE) stands at 11.59%, signalling moderate efficiency in capital utilisation. However, long-term growth concerns persist as operating profit has declined at an annualised rate of -9.97% over the past five years. The operating profit to interest coverage ratio for the quarter is at a low 10.10 times, and operating profit to net sales ratio is also subdued at 12.34%, highlighting margin pressures. These factors temper the overall quality rating, which remains cautious despite some strengths.
Valuation Upgrade: From Attractive to Very Attractive
The valuation grade for Alembic Pharmaceuticals has been upgraded from attractive to very attractive, driven by several key financial ratios. The company’s price-to-earnings (PE) ratio is 21.90, which is significantly lower than many of its peers such as Ajanta Pharma (39.61) and Gland Pharma (38.98), indicating a relative discount. The price-to-book value ratio is 2.83, while the enterprise value to EBITDA ratio stands at 15.47, both suggesting reasonable pricing in relation to earnings and asset base.
Additionally, the PEG ratio of 0.78 reflects undervaluation relative to earnings growth, as the company’s profits have risen by 28.2% over the past year despite a negative stock return. Dividend yield is modest at 1.35%, but the return on equity (ROE) of 12.93% supports a sustainable profitability profile. Enterprise value to capital employed is low at 2.51, reinforcing the very attractive valuation status. This valuation improvement is a key factor in the upgrade to a Hold rating.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Financial Trend: Flat Recent Performance Amid Mixed Returns
Financial trends for Alembic Pharmaceuticals present a nuanced picture. The company’s stock price has underperformed the broader market over the past year, delivering a negative return of -17.63% compared to the Sensex’s -7.08%. Year-to-date, the stock is down by -3.89%, though this is less severe than the Sensex’s -9.06% decline. Over longer horizons, Alembic has outperformed the Sensex over three and ten years, with returns of 28.14% and 40.14% respectively, compared to 19.75% and 185.51% for the Sensex.
Despite the recent flat quarterly results and subdued operating profit margins, the company’s profits have grown by 28.2% in the last year, indicating underlying operational resilience. Institutional investors hold a significant 20.41% stake, reflecting confidence from knowledgeable market participants. However, the poor long-term growth in operating profit and recent flat financials justify a cautious stance on financial trends.
Technical Analysis: Shift from Mildly Bearish to Sideways
The most significant driver behind the upgrade to Hold is the improvement in Alembic Pharmaceuticals’ technical outlook. The technical grade has shifted from mildly bearish to sideways, signalling a stabilisation in price momentum. Weekly technical indicators show a mildly bullish MACD and bullish Bollinger Bands, supported by a bullish KST and On-Balance Volume (OBV) on both weekly and monthly charts. Dow Theory assessments are mildly bullish on both weekly and monthly timeframes.
Conversely, monthly MACD and Bollinger Bands remain bearish, and daily moving averages are mildly bearish, indicating some caution in the short term. The Relative Strength Index (RSI) on weekly and monthly charts shows no clear signal, suggesting the stock is neither overbought nor oversold. Overall, the technical picture has improved sufficiently to warrant a more positive rating, reflecting a potential base formation and reduced downside risk.
Price and Market Context
At the time of the rating change, Alembic Pharmaceuticals was trading at ₹815.20, down 1.49% from the previous close of ₹827.55. The stock’s 52-week high stands at ₹1,064.70, with a low of ₹635.30, indicating a wide trading range over the past year. Intraday volatility was evident with a high of ₹847.65 and a low of ₹807.25 on the day of the upgrade. These price movements reflect ongoing market uncertainty but also highlight the stock’s potential for recovery given its valuation and technical improvements.
Holding Alembic Pharmaceuticals Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Peer Comparison and Market Positioning
When compared with its pharmaceutical peers, Alembic Pharmaceuticals stands out for its valuation attractiveness. While companies like Ajanta Pharma and Gland Pharma trade at PE ratios near 40 and EV/EBITDA multiples above 20, Alembic’s PE of 21.90 and EV/EBITDA of 15.47 offer a more compelling entry point. Its PEG ratio of 0.78 also suggests undervaluation relative to earnings growth, contrasting with higher PEGs among peers.
However, the company’s recent underperformance relative to the BSE500 index, which declined by only -1.52% over the past year, highlights challenges in market sentiment. The stock’s higher volatility and weaker returns underscore the need for cautious optimism. Institutional holdings at 20.41% provide some reassurance, as these investors typically conduct rigorous fundamental analysis before committing capital.
Outlook and Investment Implications
The upgrade to a Hold rating reflects a balanced view of Alembic Pharmaceuticals’ prospects. The improved technical indicators and very attractive valuation metrics provide a foundation for potential recovery and moderate upside. However, flat recent financial performance, weak long-term operating profit growth, and underperformance relative to the broader market temper enthusiasm.
Investors should monitor upcoming quarterly results for signs of renewed growth and margin improvement. The company’s ability to maintain low leverage and generate consistent returns on capital will be critical to sustaining investor confidence. Given the current sideways technical trend and valuation discount, Alembic Pharmaceuticals may appeal to investors seeking a cautiously optimistic exposure to the pharmaceuticals sector with a focus on value and technical stability.
Summary of Rating Change Drivers
- Quality: Stable debt servicing and moderate ROCE offset by flat quarterly results and weak long-term profit growth.
- Valuation: Upgraded to very attractive due to low PE, EV/EBITDA, PEG ratio, and favourable dividend yield compared to peers.
- Financial Trend: Mixed returns with recent flat performance but strong profit growth and high institutional ownership.
- Technicals: Shift from mildly bearish to sideways trend with bullish weekly indicators and improved momentum.
Overall, the Hold rating upgrade for Alembic Pharmaceuticals Ltd. reflects a nuanced assessment that balances valuation appeal and technical improvements against ongoing financial challenges and market underperformance.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
